UPC Analytics
ENDE
Overview · Filed: —

ACT_16116/2024

NOVEL ANTITUMORAL USE OF CABAZITAXEL

InfringementMain Infringement ActionMunich LDInfringement Action—
OverviewDecisionsDocumentsTimeline
Parties

Claimants

  • Sanofi SA (and related Sanofi entities)
Reps: Frédéric Chevallier (McDermott Will & Emery)

Respondents

  • Accord Healthcare entities
  • STADAPHARM GmbH
  • STADA Arzneimittel AG
  • Reddy Pharma SAS
  • betapharm Arzneimittel GmbH
  • Zentiva France
  • Zentiva Pharma GmbH
  • Zentiva, k.s.
Reps: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Judges
  • Matthias ZigannPresiding Judge / Judge-Rapporteur
Patents
  • EP 2 493 466
CPC codes: A61K38/193, A61K31/573, A61P35/04, A61K31/164, A61K31/56, A61P43/00, A61P13/08, A61P15/00, A61K31/337, A61P35/00, A61K45/06, A61P25/16

Technology area: Pharmaceuticals · Oncology

Sector: Pharmaceutical & Medical

Outcome
Procedural onlyProcedural only (no substantive ruling yet)
Filed: —
First decided: Sep 15, 2025
Language: —